CSF2 and Parkinson disease: Specifically, for neurodegenerative diseases, early investigations suggest innate immune modulation and illustrate GM-CSF/sargramostim potential to ameliorate symptoms and pathology of Alzheimer’s and Parkinson’s Diseases, among others (33–36).